160 related articles for article (PubMed ID: 37686015)
1. Ascites-Derived Organoids to Depict Platinum Resistance in Gynaecological Serous Carcinomas.
Arias-Diaz AE; Ferreiro-Pantin M; Barbazan J; Perez-Beliz E; Ruiz-Bañobre J; Casas-Arozamena C; Muinelo-Romay L; Lopez-Lopez R; Vilar A; Curiel T; Abal M
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686015
[TBL] [Abstract][Full Text] [Related]
2. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
3. Generation and Culturing of High-Grade Serous Ovarian Cancer Patient-Derived Organoids.
Graham O; Rodriguez J; van Biljon L; Fashemi B; Graham E; Fuh K; Khabele D; Mullen M
J Vis Exp; 2023 Jan; (191):. PubMed ID: 36688549
[TBL] [Abstract][Full Text] [Related]
4. Malignant ascites occurs most often in patients with high-grade serous papillary ovarian cancer at initial diagnosis: a retrospective analysis of 191 women treated at Bayreuth Hospital, 2006-2015.
Krugmann J; Schwarz CL; Melcher B; Sterlacci W; Ozalinskaite A; Lermann J; Agaimy A; Vieth M
Arch Gynecol Obstet; 2019 Feb; 299(2):515-523. PubMed ID: 30415435
[TBL] [Abstract][Full Text] [Related]
5. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA
Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581
[TBL] [Abstract][Full Text] [Related]
6. Intraindividual genomic heterogeneity of high-grade serous carcinoma of the ovary and clinical utility of ascitic cancer cells for mutation profiling.
Choi YJ; Rhee JK; Hur SY; Kim MS; Lee SH; Chung YJ; Kim TM; Lee SH
J Pathol; 2017 Jan; 241(1):57-66. PubMed ID: 27741368
[TBL] [Abstract][Full Text] [Related]
7. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
Lee JM; Nair J; Zimmer A; Lipkowitz S; Annunziata CM; Merino MJ; Swisher EM; Harrell MI; Trepel JB; Lee MJ; Bagheri MH; Botesteanu DA; Steinberg SM; Minasian L; Ekwede I; Kohn EC
Lancet Oncol; 2018 Feb; 19(2):207-215. PubMed ID: 29361470
[TBL] [Abstract][Full Text] [Related]
8. Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine.
Nero C; Vizzielli G; Lorusso D; Cesari E; Daniele G; Loverro M; Scambia G; Sette C
J Exp Clin Cancer Res; 2021 Mar; 40(1):116. PubMed ID: 33789687
[TBL] [Abstract][Full Text] [Related]
9. Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer.
Silva R; Glennon K; Metoudi M; Moran B; Salta S; Slattery K; Treacy A; Martin T; Shaw J; Doran P; Lynch L; Jeronimo C; Perry AS; Brennan DJ
Int J Cancer; 2023 Jul; 153(1):120-132. PubMed ID: 36883413
[TBL] [Abstract][Full Text] [Related]
10. Single-cell RNA-sequencing analysis reveals divergent transcriptome events between platinum-sensitive and platinum-resistant high-grade serous ovarian carcinoma.
Wang Z; Yang L; Su X; Wu X; Su R
J Gene Med; 2023 Oct; 25(10):e3504. PubMed ID: 36994597
[TBL] [Abstract][Full Text] [Related]
11. Ubiquitin-Proteasome Axis, Especially Ubiquitin-Specific Protease-17 (
Yildirim N; Kocal GC; Isik Z; Saatli B; Saygili U; Uysal T; Ulukus C; Koyuncuoglu M; Ellidokuz H; Basbinar Y
Reprod Sci; 2019 Jun; 26(6):794-805. PubMed ID: 30198418
[TBL] [Abstract][Full Text] [Related]
12. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
13. Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.
Roque DM; Bellone S; English DP; Buza N; Cocco E; Gasparrini S; Bortolomai I; Ratner E; Silasi DA; Azodi M; Rutherford TJ; Schwartz PE; Santin AD
Cancer; 2013 Jul; 119(14):2582-92. PubMed ID: 23585021
[TBL] [Abstract][Full Text] [Related]
14. Microparticles from ovarian carcinomas are shed into ascites and promote cell migration.
Press JZ; Reyes M; Pitteri SJ; Pennil C; Garcia R; Goff BA; Hanash SM; Swisher EM
Int J Gynecol Cancer; 2012 May; 22(4):546-52. PubMed ID: 22315094
[TBL] [Abstract][Full Text] [Related]
15. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
[TBL] [Abstract][Full Text] [Related]
16. Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing.
Bi J; Newtson AM; Zhang Y; Devor EJ; Samuelson MI; Thiel KW; Leslie KK
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34200645
[TBL] [Abstract][Full Text] [Related]
17. Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma.
Kerr EH; Frederick PJ; Egger ME; Stockard CR; Sellers J; DellaManna D; Oelschlager DK; Amm HM; Eltoum IE; Straughn JM; Buchsbaum DJ; Grizzle WE; McNally LR
Ann Surg Oncol; 2013 Sep; 20(9):3059-65. PubMed ID: 23525731
[TBL] [Abstract][Full Text] [Related]
18. A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer.
Hoare JI; Hockings H; Saxena J; Silva VL; Haughey MJ; Wood GE; Nicolini F; Mirza H; McNeish IA; Huang W; Maniati E; Graham TA; Lockley M
Gynecol Oncol; 2022 Oct; 167(1):96-106. PubMed ID: 35918200
[TBL] [Abstract][Full Text] [Related]
19. Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.
Mignogna C; Staropoli N; Botta C; De Marco C; Rizzuto A; Morelli M; Di Cello A; Franco R; Camastra C; Presta I; Malara N; Salvino A; Tassone P; Tagliaferri P; Barni T; Donato G; Di Vito A
J Ovarian Res; 2016 May; 9(1):31. PubMed ID: 27209210
[TBL] [Abstract][Full Text] [Related]
20. Developing patient-derived organoids to predict PARP inhibitor response and explore resistance overcoming strategies in ovarian cancer.
Tao M; Sun F; Wang J; Wang Y; Zhu H; Chen M; Liu L; Liu L; Lin H; Wu X
Pharmacol Res; 2022 May; 179():106232. PubMed ID: 35462012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]